Structure Therapeutics Says Experimental Obesity Pill Shows No Signs of Liver Injury

What's happening

Structure Therapeutics reported new data showing that its experimental obesity pill did not show evidence of liver injury during testing.

The results were particularly important because concerns about liver toxicity have affected several obesity-drug programs in recent years.

What's changing / Business impact

The positive safety results improve the company's chances of advancing the drug through future clinical trials.

The obesity market has become one of the most valuable areas in healthcare, with companies racing to develop alternatives to injectable drugs like Ozempic, Wegovy, Zepbound, and Mounjaro.

Why this matters

Many patients prefer pills over injections.

If companies can develop effective obesity pills with strong safety profiles, they could dramatically expand access to treatment and compete with today's blockbuster injectable medicines.

Safety is especially important because obesity drugs are often taken for long periods of time, meaning even small risks can become significant.